Windlas Biotech (BOM:543329) Debt-to-Equity : N/A (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Windlas Biotech Debt-to-Equity?

Windlas Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Windlas Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Windlas Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2024 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Windlas Biotech's Debt-to-Equity or its related term are showing as below:

BOM:543329' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.17
Current: 0.04

During the past 6 years, the highest Debt-to-Equity Ratio of Windlas Biotech was 0.17. The lowest was 0.01. And the median was 0.02.

BOM:543329's Debt-to-Equity is ranked better than
84.94% of 817 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs BOM:543329: 0.04

Windlas Biotech Debt-to-Equity Historical Data

The historical data trend for Windlas Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windlas Biotech Debt-to-Equity Chart

Windlas Biotech Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.14

0.16

0.02

0.01

Windlas Biotech Quarterly Data
	Mar19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.01	N/A	0.04	N/A

Competitive Comparison of Windlas Biotech's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Windlas Biotech's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Windlas Biotech's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Windlas Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Windlas Biotech's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.23	+	20.18)	/	4499.36
	=	0.01

Windlas Biotech's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Windlas Biotech (BOM:543329) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Windlas Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Windlas Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Windlas Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Windlas Biotech Ltd (BOM:543329) » Definitions » Debt-to-Equity

Traded in Other Exchanges

WINDLAS:India

Address

Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001

Website

https://www.windlas.com

Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.

Windlas Biotech Headlines

No Headlines